C3 treats first European patient with CellSpray
Friday, 28 October, 2005
Tissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has treated a first European patient with its burns therapy CellSpray at Halle, in Germany.
CellSpray is intended for use in patients with between 30 per cent and 90 per cent of injuries to the body surface. It was launched in Europe in September, at the European Burns Association meeting in Portugal. Surgeons and medical practitioners in 20 hospitals in German speaking countries have been trained in using the CellSpray technology.
In July, the first patient was treated with C3's CellSpray XP, which is intended for use in patients with injuries of 10 to 30 per cent of the body.
CellSpray is available for sale in Austria, Denmark, Germany, The Netherlands and the UK, while CellSpray XP is also available for sale in Switzerland and Italy.
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
